Organization (Industry)
Senseonics Holdings, Inc.
ClinicalTrials.gov lists Senseonics Holdings, Inc. as lead sponsor of 11 trials.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 1 registered with a 2026 start date. The dashed outline is the pace from the 1 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 0.6 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Senseonics Holdings, Inc.: 11 lead-sponsored trials and 2 legal-entity registrations.
Disease areas (3)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Diabetes Mellitus | 12 |
| Diabetes Mellitus, Type 1 | 8 |
| Diabetes Mellitus, Type 2 | 8 |
Trials by start year as sponsor or collaborator (8)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2025 | 1 |
| 2021 | 2 |
| 2019 | 1 |
| 2018 | 2 |
| 2017 | 1 |
| 2016 | 3 |
| 2014 | 1 |
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 1 of 2 hit target (n=2) | 0 of 2 on time (n=2) |
Journals published in (2)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Diabetes care | 1 |
| Diabetes technology & therapeutics | 1 |
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 153 | 52 | 2025-12-16 |
SEC-reported annual financials (11)
Shown in this order: newest fiscal year first; SEC EDGAR XBRL companyfacts, USD as reported.
| Fiscal year | Revenue (USD) | Net income (USD) | R&D (USD) |
|---|---|---|---|
| 2025 | 35,257,000 | -69,113,000 | 31,592,000 |
| 2024 | 22,472,000 | -78,616,000 | 41,144,000 |
| 2023 | 22,390,000 | -60,392,000 | 48,752,000 |
| 2022 | 16,389,000 | 142,119,000 | 39,719,000 |
| 2021 | 1,394,000 | -302,474,000 | 27,217,000 |
| 2020 | 1,368,000 | -175,168,000 | 20,413,000 |
| 2019 | 4,924,000 | -115,549,000 | 38,430,000 |
| 2018 | 2,039,000 | -93,971,000 | 31,863,000 |
| 2017 | 529,000 | -59,101,000 | 30,735,000 |
| 2016 | 332,000 | -43,930,000 | 26,347,000 |
Showing 10 of 11 fiscal years.
Financing and grant events (61)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2026-06-08 | Other financing | not disclosed | Sec extracted |
| 2026-06-01 | Other financing | not disclosed | Sec extracted |
| 2026-05-01 | Debt financing | 35 | Sec extracted |
| 2026-04-30 | Public offering | not disclosed | Sec extracted |
| 2026-04-30 | Debt financing | not disclosed | Sec extracted |
Showing 5 of 61 events.
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| NAI | 2 |
FDA recalls (1)
| Product | Classification | Initiated |
|---|---|---|
| Eversense CGM SENSOR (FG-4200-00-301)-Continuous Glucose Monitor | Class II | 2019-09-18 |
FDA import refusals (1)
| Refused import lines | Latest refusal |
|---|---|
| 1 | 2025-10-06 |
Manufacturing and distribution sites (1)
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| Senseonics, Inc. | Germantown, US | FDA |
Climate targets, as filed (1)
| Reporting year | Net-zero target |
|---|---|
| 2025 | not disclosed |
Workforce and board diversity, as filed (1)
| Reporting year | Workforce % women | Board % women |
|---|---|---|
| 2025 | not disclosed | not disclosed |
Organization relationships (1)
| Related organization | Relationship | Evidence |
|---|---|---|
| Kinderkrankenhaus auf der Bult | Co sponsors trial with | 1 |
Latest dated events (232)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-06-08 | Financing | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2026-06-01 | Financing | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2026-05-01 | Debt facility | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2026-04-30 | Public offering | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2026-04-30 | Debt facility | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
Showing 5 of 232 events.
Biomarker capability evidence (1)
| Gene | Role | Evidence |
|---|---|---|
| SAT1 | Trial sponsor | Mentioned in trial text |
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, active development programs, approved assets, fda warning letters, fda untitled letters, clia clinical laboratory certificates, and biomarkers this organization publishes on.